Rinne, Juha O., Brooks, David J., Rossor, Martin N., Fox, Nick C., Bullock, Roger, Klunk, William E., Mathis, Chester A., Blennow, Kaj, Barakos, Jerome, Okello, Aren A., Rodriguez Martinez de Liano, Sofia, Liu, Enchi, Koller, Martin, Gregg, Keith M., Schenk, Dale, Black, Ronald, Grundman, Michael

Background: Carbon-11-labelled Pittsburgh compound B ((11)C-PiB) PET is a marker of cortical fibrillar amyloid-beta load in vivo. We used (11)C-PiB PET to investigate whether bapineuzumab, a humanised anti-amyloid-beta monoclonal antibody, would reduce cortical fibrillar amyloid-beta load in patients with Alzheimer’s disease.; Methods: Patients with mild-to-moderate Alzheimer’s disease were randomly assigned to receive intravenous bapineuzumab or […]

Relkin, Norman R., Szabo, Paul, Adamiak, Basia, Burgut, Tuna, Monthe, Carmen, Lent, Richard W., Younkin, Steven, Younkin, Linda, Schiff, Richard, Weksler, Marc E.

Intravenous immunoglobulin (IVIg) has been proposed as a potential agent for Alzheimer’s disease (AD) immunotherapy because it contains antibodies against beta-amyloid (Abeta). We carried out an open label dose-ranging study in 8 mild AD patients in which IVIg was added to approved AD therapies for 6 months, discontinued, and then resumed for another 9 months. […]

Flanagan, Eoin P., McKeon, Andrew, Lennon, Vanda A., Boeve, Bradley F., Trenerry, Max R., Tan, K. Meng, Drubach, Daniel A., Josephs, Keith A., Britton, Jeffrey W., Mandrekar, Jayawant N., Lowe, Val, Parisi, Joseph E., Pittock, Sean J.

Objective: To define the diagnostic characteristics and predictors of treatment response in patients with suspected autoimmune dementia.; Patients and Methods: Between January 1, 2002, and January 1, 2009, 72 consecutive patients received immunotherapy for suspected autoimmune dementia. Their baseline clinical, radiologic, and serologic characteristics were reviewed and compared between patients who were responsive to immunotherapy […]